Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenpu Penyanke Granules is a Traditional Chinese Medicine (TCM) compound developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic pelvic pain associated with the sequelae of pelvic inflammatory disease (PID). Classified as a Class 1.1 new TCM drug in China, it is specifically formulated for patients presenting with the TCM pattern of damp-heat with blood stasis. The formulation is designed to clear heat, eliminate dampness, and activate blood circulation to alleviate pain and resolve inflammation in the pelvic cavity. It is currently in Phase 3 clinical development in China, with trials evaluating its efficacy and safety in women suffering from persistent pelvic pain following PID.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenpu Penyanke Granules.